ArticleReviews in cardiovascular medicine2026
Predictive Value of the Systemic Immune-Inflammation Index for Cardiovascular Events in Patients With Chronic Total Coronary Occlusion.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This large-scale cohort study aimed to evaluate the prognostic role of the systemic immune-inflammation index (SII) in patients with chronic total occlusion (CTO) undergoing percutaneous coronary intervention (PCI). Methods: A total of 3107 patients with CTO lesions who underwent PCI were enrolled in this study. Clinical characteristics were collected, and post-discharge major adverse cardiovascular events (MACEs) were recorded during follow-up, including all-cause mortality, non-fatal myocardial infarction, unplanned revascularization, and heart failure-related readmission. Patients were stratified into three groups according to SII tertiles: the low SII group (SII ≤447.66, n = 1036), the intermediate SII group (447.66 < SII < 679.89, n = 1039), and the high SII group (SII ≥679.89, n = 1032). Results: Over a median follow-up of 2.58 (2.33-2.92) years, 356 (11.5%) MACEs occurred, including 49 (1.6%) all-cause deaths, 105 (3.4%) non-fatal myocardial infarctions, 164 (5.3%) revascularizations, and 38 (1.2%) heart failure rehospitalizations. Multivariable Cox regression analyses demonstrated that elevated SII was independently linked to higher risks of MACEs (hazard ratio [HR] = 1.51, 95% confidence interval [CI]: 1.20-1.90; Conclusions: Baseline SII is a reliable and independent predictor of MACEs in patients with CTO after PCI, with superior predictive performance compared with conventional inflammatory markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.